STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

ELACESTRANT

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
ELACESTRANT HYDROCHLORIDE	ORSERDU	48658		GPI-10 (2140372010)	

GUIDELINES FOR USE

1. Does the patient have a diagnosis of advanced or metastatic breast cancer and meet **ALL** of the following criteria?
   - The patient's breast cancer is estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative with estrogen receptor 1 gene (ESR1) mutation(s)
   - The patient has disease progression following endocrine therapy

   If yes, **approve for 12 months by GPID or GPI-14 for all strengths, with the following quantity limits:**
   - **345 mg: #1 per day.**
   - **86 mg: #3 per day.**

   If no, do not approve.
   DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named **ELACESTRANT (Orserdu)** requires the following rule(s) be met for approval:
   A. You have advanced or metastatic breast cancer (breast cancer that has spread to other parts of the body)
   B. Your breast cancer is estrogen receptor (ER: type of protein)-positive, human epidermal growth factor receptor 2 (HER2: type of protein)-negative with estrogen receptor 1 (ESR1: a gene) mutation(s)
   C. You have disease progression following endocrine therapy (disease has worsened after using a type of hormone therapy)

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE

STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

ELACESTRANT

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Orserdu.

REFERENCES

- Orserdu [Prescribing Information]. New York, NY: Stemline Therapeutics, Inc.; January 2023.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A
Commercial Effective: 07/01/23
Created: 05/23
Client Approval: 05/23
P&T Approval: 04/23